MDIN (MedGen Inc) recently has been on the move from its triple zero lows surging to a high of .0016 cents on Wednesday as investors had taken deep interest in this undervalued BIOTECH company. MDIN is a BIOTECH company with some serious due diligence behind it.
BIOTECH stocks have been quite the money maker as seen with our past ARYC Alert which saw a massive move from a low of .0008 Cents from our Alert to just over .10 cents.
There are a number of significant developments anticipated to be in the works for MDIN (MedGen, Inc) with the addition of a brand new management team now on-board which consists of intelligent doctors & scientists. The recent reverse split cancellation and Managements plans to remove the C/E from OTC Markets coupled with several major Acquisitions already closed and over a dozen more anticipated to be in the works followed by a major news campaign expected to kick off shortly certainly bodes well for a massive move over the next 3 to 6 months based on our analysis.
MedGen which trades under the ticker symbol MDIN on the OTC Markets is a Greensboro, NC Based MedTech and Lifesciences Company Focused on Technology Commercialization and Investment. The company operates in Four Segments, including Biomedical, Healthcare, Precision Medicine and Pharmaceutical. MedGen Portfolio Companies and Divisions offers a range of Products, Solutions and Services for Sale and Licensing.
The Company currently has a number of products in development including Additive Manufacturing @ the Micro & Nanoscale with Initial Focus on Biotechnology Utilizing 3D Bioprinting. Producing Consumable Materials and Products that Mimic the Natural Shape of Tissues in the Human Body. Artificial Human Organs (Extracorporeal). Application 1 – Liver Assist Device. Application 2 – Drug Development/ Testing. Reducing FDA Rejection. Medical Device Coatings. Smart Bandages. eTextiles and Printed/ Flexible Electronics.
The company recently announced the cancellation of their reverse split. They also reduced their O/S from 178 Billion Shares to 2.8 Billion Shares as they continue to restructure their Share structure and grow the company with the ultimate goal of bringing significant Shareholder value to investors.
The company has had several key Acquisitions this year which positions themselves for massive growth throughout the remainder of 2018 with over a dozen more Acquisitions in the pipeline expected throughout 2019.
One of the most exciting and promising Acquisition which MDIN (MedGen, Inc) recently undertook this year was for Thor Biom3dical which specializes in Artificial Human Organ BIOTECHNOLOGY.
The second major Acquisition was for Emb3ded Advanced Technologies, Inc.
Embe3ded Advanced Technologies Inc is one of several mergers showing Product Demand.
“Our Products and Services are in Demand for the Biomedical, Regenerative and Precision Medicine Industries.” http://www.emb3ded.com/
“Our Products and Services are in Demand for the Biomedical, Regenerative and Precision Medicine Industries.” http://www.emb3ded.com/
MANAGEMENT
Brand New management team now on-board which consists of intelligent doctors & scientists.
CEO Johnny Rodrigues is Founder & Managing Partner of: http://www.rodinnovation.com https://www.slideshare.net/
Impressive 3D BIOTECH Organ Printing Machine designed by Raghu Panduranga!
MedGen Chief Scientist Tim Thomson used to work for Dow Chemical. Since 1990, he has been doing his own independent research, wrote three books on polyurethane chemistry and conducted seminars in the US and Europe. Mr. Tim Thomson has been granted 7 patents and has several in the works. He has also consulted for dozens of companies.
CONTACT DETAILS
343-333-3325
MedGen, Inc Facility
Brand New management team now on-board which consists of intelligent doctors & scientists.
CEO Johnny Rodrigues is Founder & Managing Partner of: http://www.rodinnovation.com https://www.slideshare.net/
Impressive 3D BIOTECH Organ Printing Machine designed by Raghu Panduranga!
MedGen Chief Scientist Tim Thomson used to work for Dow Chemical. Since 1990, he has been doing his own independent research, wrote three books on polyurethane chemistry and conducted seminars in the US and Europe. Mr. Tim Thomson has been granted 7 patents and has several in the works. He has also consulted for dozens of companies.
CONTACT DETAILS
2901 East Gate City Blvd. Suite 2400
Greensboro, NC 27401
www.medgencorp.com343-333-3325
MedGen, Inc Facility
In conclusion we believe MDIN (MedGen, Inc) is an extremely undervalued investment and shows tremendous promise for early investors at current low sub-penny levels. With the revolutionary 3D Human Organ BIOTECH Printing Technology coupled with the vast array of other promising assets the company could potentially see up to .03 to .05 Cents in Share Price in the coming months.
That is all for now readers!
Good luck & Happy Trading!
Regards,
PSG Team
DisclaimerAll of our Penny Stock Alerts and Picks mentioned are intended for informational purposes as per Due Diligence only and not intended as an offer to buy or sell securities. We are not Licensed security professionals nor can we offer investment advice on whether to buy or sell any of the securities mentioned in our newsletters. Penny Stock Geeks is not liable for any loss or damages you may have received as a result of any securities purchased or mentioned through our communicative efforts. We have not been compensated for profiling MDIN (MedGen, Inc). We may buy or sell MDIN (MedGen, Inc) shares in the open market at any given time. Investing in Penny Stocks has a high risk factor and may cause you to lose some or all of your investment. Never invest in Penny Stocks with money you cannot afford to lose. Please invest wisely after performing your own Due Diligence as well.
